Jul 25, 2013 7:00am EDT NeoGenomics Introduces Comprehensive Myelodysplastic Syndrome (MDS) Molecular Testing
Apr 25, 2013 7:00am EDT NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter
